These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 28117387

  • 21. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
    Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.
    Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
    [Abstract] [Full Text] [Related]

  • 22. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [Abstract] [Full Text] [Related]

  • 23. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [Abstract] [Full Text] [Related]

  • 24. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
    Kim H, Jung G, Kim JH, Byun SS, Hong SK.
    Sci Rep; 2021 Aug 31; 11(1):17447. PubMed ID: 34465825
    [Abstract] [Full Text] [Related]

  • 25. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH, Kweldam CF, Hollemans E, Kümmerlin IP, Nieboer D, Verhoef EI, Remmers S, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ.
    Eur Urol; 2020 Feb 31; 77(2):191-198. PubMed ID: 31439369
    [Abstract] [Full Text] [Related]

  • 26. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S, de Cobelli O, Cozzi G, Peveri G, Bagnardi V, Catellani M, Di Trapani E, Mistretta FA, Pricolo P, Conti A, Alessi S, Marvaso G, Ferro M, Matei DV, Renne G, Jereczek-Fossa BA, Petralia G, Musi G.
    BJU Int; 2020 Jul 31; 126(1):104-113. PubMed ID: 32150328
    [Abstract] [Full Text] [Related]

  • 27. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.
    Kim L, Boxall N, George A, Burling K, Acher P, Aning J, McCracken S, Page T, Gnanapragasam VJ.
    BMC Med; 2020 Apr 17; 18(1):95. PubMed ID: 32299423
    [Abstract] [Full Text] [Related]

  • 28. Prostate cancer age-standardised incidence increase between 2006 and 2016 in Gauteng Province, South Africa: A laboratory data-based analysis.
    Cassim N, Ahmad A, Wadee R, Rebbeck TR, Glencross DK, George JA.
    S Afr Med J; 2020 Dec 14; 111(1):26-32. PubMed ID: 33404002
    [Abstract] [Full Text] [Related]

  • 29. Performance of prostate health index and PSA density in a diverse biopsy-naïve cohort with mpMRI for detecting significant prostate cancer.
    Carbunaru S, Stinson J, Babajide R, Hollowell CMP, Yang X, Sekosan M, Ferrer K, Kajdacsy-Balla A, Abelleira J, Ruden M, King-Lee P, Dalton DP, Casalino DD, Kittles RA, Gann PH, Schaeffer EM, Murphy AB.
    BJUI Compass; 2021 Nov 14; 2(6):370-376. PubMed ID: 35474697
    [Abstract] [Full Text] [Related]

  • 30. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.
    Eur Urol; 2014 Dec 14; 66(6):1116-24. PubMed ID: 25052213
    [Abstract] [Full Text] [Related]

  • 31. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
    Chiu PK, Lam TY, Ng CF, Teoh JY, Cho CC, Hung HY, Hong C, Roobol MJ, Chu WC, Wong SY, Sung JJ.
    Asian J Androl; 2023 Nov 01; 25(6):674-679. PubMed ID: 37534902
    [Abstract] [Full Text] [Related]

  • 32. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
    Furuya K, Kawahara T, Narahara M, Tokita T, Fukui S, Imano M, Mitome T, Ito Y, Izumi K, Osaka K, Yokomizo Y, Hayashi N, Hasumi H, Nawata S, Kawano T, Yao M, Uemura H.
    Scand J Urol; 2017 Aug 01; 51(4):251-257. PubMed ID: 28351193
    [Abstract] [Full Text] [Related]

  • 33. Gleason score 5 + 3 = 8 (grade group 4) prostate cancer-a rare occurrence with contemporary grading.
    Kryvenko ON, Williamson SR, Schwartz LE, Epstein JI.
    Hum Pathol; 2020 Mar 01; 97():40-51. PubMed ID: 31923450
    [Abstract] [Full Text] [Related]

  • 34. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, Blanchet JS, Semjonow A.
    BJU Int; 2016 Jan 01; 117(1):72-9. PubMed ID: 25818705
    [Abstract] [Full Text] [Related]

  • 35. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
    Morote J, Celma A, Planas J, Placer J, Ferrer R, de Torres I, Pacciuci R, Olivan M.
    Actas Urol Esp; 2016 Jan 01; 40(6):378-85. PubMed ID: 26923032
    [Abstract] [Full Text] [Related]

  • 36. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
    Flood TA, Schieda N, Keefe DT, Breau RH, Morash C, Hogan K, Belanger EC, Mai KT, Robertson SJ.
    Virchows Arch; 2016 Sep 01; 469(3):313-9. PubMed ID: 27394432
    [Abstract] [Full Text] [Related]

  • 37. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV, Guseinov RG, Skryabin ON, Orlov IN, Martov AG.
    Urologiia; 2018 Jul 01; (3):92-97. PubMed ID: 30035426
    [Abstract] [Full Text] [Related]

  • 38. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
    Schwen ZR, Mamawala M, Tosoian JJ, Druskin SC, Ross AE, Sokoll LJ, Epstein JI, Carter HB, Gorin MA, Pavlovich CP.
    BJU Int; 2020 Sep 01; 126(3):373-378. PubMed ID: 32367635
    [Abstract] [Full Text] [Related]

  • 39. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
    Huang YP, Lin TP, Cheng WM, Wei TC, Huang IS, Fan YH, Lin CC, Huang EYH, Chung HJ, Kuo JY, Wu HHH, Lu SH, Chang YH, Lin ATL, Huang WJS.
    J Chin Med Assoc; 2019 Nov 01; 82(11):835-839. PubMed ID: 31425303
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.